Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Simeprevir Formulations in Healthy Adults
NCT02385071Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2015
- Primary completion
- Sep 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of simeprevir in hepatitis C (HCV) (12 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Reach Maximum Plasma Concentration at 72 hours and 4 more. Started Apr 2015; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02385071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385071.